eligibility_summary
Adults (>=18) with multiple myeloma per 2014 IMWG, measurable disease (M-protein or FLC criteria), ECOG 0-1, life expectancy >=3 months, adequate hematologic/hepatic/renal function, able to consent. Exclude CNS involvement, active infection (<=14 days), HIV/HBV/HCV, recent anti-myeloma therapy, live vaccines (<=28 days), major surgery (<=28 days), autoimmune disease, or severe antibody/MBS314 component allergies.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: MBS314 (intravenous), a novel asymmetric trivalent, tri-specific humanized antibody (biologic immunotherapy). Mechanism: engineered to bind three targets simultaneously to enhance immune-mediated killing of multiple myeloma cells, the registry does not disclose the exact antigen specificities or whether the construct redirects T cells or relies on Fc effector functions. Cells/pathways targeted: malignant plasma cells in relapsed/refractory multiple myeloma, intended engagement of immune-activation pathways typical of multi-specific antibodies, but specific receptors/pathways are not specified in the listing.